| Southern Ocean Center | |
| 1361 Route 72 West, Manahawkin, New Jersey 08050 | |
| (609) 978-0600 | |
| Name | Southern Ocean Center |
|---|---|
| Location | 1361 Route 72 West, Manahawkin, New Jersey |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 136 |
| Occupancy Rate | 72.87% |
| Medicare ID (CCN) | 315332 |
| Legal Business Name | 1361 Route 72 West Operations Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1366626665 |
| Organization Name | 1361 ROUTE 72 WEST OPERATIONS LLC |
| Doing Business As | SOUTHERN OCEAN CENTER |
| Address | 1361 Route 72 W, Manahawkin, NJ 08050 |
| Phone Number | 609-978-0600 |
News Archive
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.
Medovex Corp., a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX System under the most stringent standards required by FDA and other regulatory agencies.
Medicare and the health law also are emerging as flashpoints in Pennsylvania's Senate contest and various House races.
MEDSEEK, the leading provider of healthcare enterprise portal connectivity solutions, today announced the acquisition of 58 new hospital clients and a 53 percent increase in one-year revenue backlog, as healthcare industry changes fuel demand for its eHealth solutions.
Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together.
› Verified 1 days ago
| NPI Number | 1417992942 |
| Organization Name | STAFFORD CONVALESCENT CENTER, INC |
| Doing Business As | SOUTHERN OCEAN CENTER |
| Address | 1361 Route 72 W, Manahawkin, NJ 08050 |
| Phone Number | 609-978-0600 |
News Archive
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.
Medovex Corp., a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX System under the most stringent standards required by FDA and other regulatory agencies.
Medicare and the health law also are emerging as flashpoints in Pennsylvania's Senate contest and various House races.
MEDSEEK, the leading provider of healthcare enterprise portal connectivity solutions, today announced the acquisition of 58 new hospital clients and a 53 percent increase in one-year revenue backlog, as healthcare industry changes fuel demand for its eHealth solutions.
Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together.
› Verified 1 days ago
| NPI Number | 1689953085 |
| Organization Name | GENESIS REHAB SERVICES SOUTHERN OCEAN CENTER |
| Address | 1361 Route 72 W, Manahawkin, NJ 08050 |
| Phone Number | 609-978-0600 |
News Archive
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.
Medovex Corp., a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX System under the most stringent standards required by FDA and other regulatory agencies.
Medicare and the health law also are emerging as flashpoints in Pennsylvania's Senate contest and various House races.
MEDSEEK, the leading provider of healthcare enterprise portal connectivity solutions, today announced the acquisition of 58 new hospital clients and a 53 percent increase in one-year revenue backlog, as healthcare industry changes fuel demand for its eHealth solutions.
Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.
Medovex Corp., a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX System under the most stringent standards required by FDA and other regulatory agencies.
Medicare and the health law also are emerging as flashpoints in Pennsylvania's Senate contest and various House races.
MEDSEEK, the leading provider of healthcare enterprise portal connectivity solutions, today announced the acquisition of 58 new hospital clients and a 53 percent increase in one-year revenue backlog, as healthcare industry changes fuel demand for its eHealth solutions.
Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $7170 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 16.3 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 12.59 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 30.26 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 4.33 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.78 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.71 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.05 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.37 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 6.31 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 91.82 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 42.28 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.3 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.61 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.74 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 84.07 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 95.22 | 82.93 |
News Archive
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on next-generation antibiotics, announced today that it is presenting new results of several studies designed to support the continued advancement of its lead antibiotic, TP-434, a potent new broad-spectrum intravenous antibiotic with oral stepdown potential effective against difficult-to-treat and multidrug-resistant pathogens.
Medovex Corp., a developer of medical technology products, today announced that the company conducted a successful live tissue test of the DenerveX System under the most stringent standards required by FDA and other regulatory agencies.
Medicare and the health law also are emerging as flashpoints in Pennsylvania's Senate contest and various House races.
MEDSEEK, the leading provider of healthcare enterprise portal connectivity solutions, today announced the acquisition of 58 new hospital clients and a 53 percent increase in one-year revenue backlog, as healthcare industry changes fuel demand for its eHealth solutions.
Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together.
› Verified 1 days ago
Southern Ocean Center Location: 1361 Route 72 West, Manahawkin, New Jersey 08050 Phone: (609) 978-0600 | |
Southern Ocean Medical Center Location: 1140 Route 72 West, Manahawkin, New Jersey 08050 Phone: (609) 978-4182 |